Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease (Q33891119)

29 July 2017

title

Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease (English)

1 reference

29 July 2017

5

Donald P Tashkin

1 reference

29 July 2017

1

Michael D Roth

1 reference

29 July 2017

Chi-Hong Tseng

2

1 reference

29 July 2017

Philip J Clements

3

1 reference

29 July 2017

Daniel E Furst

4

1 reference

29 July 2017

Jonathan G Goldin

6

1 reference

29 July 2017

Dinesh Khanna

7

1 reference

29 July 2017

Eric C Kleerup

8

1 reference

29 July 2017

Ning Li

9

1 reference

29 July 2017

David Elashoff

10

1 reference

29 July 2017

Robert M Elashoff

11

1 reference

29 July 2017

Scleroderma Lung Study Research Group

12

1 reference

29 July 2017

publication date

1 September 2011

1 reference

29 July 2017

published in

Arthritis & Rheumatology

1 reference

29 July 2017

volume

63

1 reference

29 July 2017

issue

9

1 reference

29 July 2017

page(s)

2797-2808

1 reference

Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910296

Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910296

Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910296

Scleroderma lung disease: evolving understanding in light of newer studies

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910296

Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910296

High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910296

Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910296

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910296

Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910296

Changes in causes of death in systemic sclerosis, 1972-2002

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910296

The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910296

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910296

Cyclophosphamide versus placebo in scleroderma lung disease.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910296

Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910296

Interstitial lung disease in systemic sclerosis: a simple staging system

28 July 2018

1 reference

Oral cyclophosphamide for active scleroderma lung disease: a decision analysis.

21 January 2018

1 reference

Severe restrictive lung disease in systemic sclerosis.

21 January 2018

1 reference

Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis

21 January 2018

1 reference

Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study

21 January 2018

1 reference

Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis

21 January 2018

1 reference

12 December 2020

Evaluation and management of scleroderma lung disease using bronchoalveolar lavage

1 reference

12 December 2020

Cyclophosphamide for scleroderma lung disease

1 reference

12 December 2020

Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre

1 reference

12 December 2020

The natural course of progressive systemic sclerosis patients with interstitial lung involvement

1 reference

12 December 2020

Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression

1 reference

12 December 2020

Identifiers

DOI

10.1002/ART.30438

1 reference

29 July 2017

1 reference

29 July 2017

1 reference